title: Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin's lymphoma. A randomized prospective study with an assessment of prognostic factors.
abstract: One hundred sixty-two patients with Stages III and IV non-Hodgkin's lymphoma of low-grade histologic type were treated with combination chemotherapy using cyclophosphamide, vincristine, and prednisolone (CVP) followed by radiotherapy to sites of previous bulk disease. The patients were randomized to receive either follow-up alone or "maintenance" chemotherapy with 2 years of intermittent chlorambucil. A complete remission was obtained in 56% of patients and the median survival was 64 months (median follow-up, 74 months). Multivariate analysis revealed stage (P less than 0.0001) and Karnofsky performance status (P = 0.021) to predict complete response (CR) and the achievement of a CR (P less than 0.0001), female sex (P = 0.008), the absence of bulk disease (P = 0.038) and low serum alkaline phosphatase (P = 0.002) to predict prolonged survival. The median relapse-free survival (RFS) of the complete responders was 41 months. A prolonged RFS was predicted by low stage (P = 0.014), low serum lactic dehydrogenase (LDH) (P = 0.045) levels, and by the administration of maintenance chlorambucil (P = 0.045). A prolonged survival of the complete responders was predicted by a low number of nodal sites of involvement with lymphoma at presentation (P = 0.022) and lack of liver involvement (P = 0.011). The administration of oral maintenance therapy with chlorambucil for a full 2 years was only possible in 38% of patients, mainly because of progression of disease and the induction of thrombocytopaenia, but despite this it prolonged the median RFS by 38 months and its use could be considered when future studies are being designed.
authors.affiliation: CRC Department of Medical Oncology, University of Manchester, Christie Hospital & Holt Radium Institute, Withington, United Kingdom.
authors.forename: W P
authors.initials: WP
authors.lastname: Steward
authors.forename: D
authors.initials: D
authors.lastname: Crowther
authors.forename: L J
authors.initials: LJ
authors.lastname: McWilliam
authors.forename: J M
authors.initials: JM
authors.lastname: Jones
authors.forename: D P
authors.initials: DP
authors.lastname: Deakin
authors.forename: I D
authors.initials: ID
authors.lastname: Todd
authors.forename: G
authors.initials: G
authors.lastname: Blackledge
authors.forename: J
authors.initials: J
authors.lastname: Wagstaff
authors.forename: J H
authors.initials: JH
authors.lastname: Scarffe
authors.forename: M
authors.initials: M
authors.lastname: Harris
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D002699:Chlorambucil / Q000008:administration & dosage / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D011446:Prospective Studies; D011897:Random Allocation; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D002699:Chlorambucil; D014750:Vincristine; D003520:Cyclophosphamide; D011241:Prednisone